Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-13
DOI
10.3389/fendo.2021.620522
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Anti–PD-1 Therapy Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma
- (2020) Raynald A. Samoa et al. DIABETES CARE
- Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis
- (2019) John George et al. PANCREATOLOGY
- Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
- (2019) H. K. Akturk et al. DIABETIC MEDICINE
- Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
- (2019) Jeroen M.k. de Filette et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
- (2018) Jordan J. Wright et al. DIABETES CARE
- Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
- (2017) James Luke Godwin et al. Journal for ImmunoTherapy of Cancer
- A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
- (2016) Young Kwang Chae et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
- (2016) Jared R. Lowe et al. Journal for ImmunoTherapy of Cancer
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- (2015) Juan Martin-Liberal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
- (2015) Mahnaz Mellati et al. DIABETES CARE
- Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
- (2015) Caroline Gaudy et al. DIABETES CARE
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Association of Ipilimumab Therapy for Advanced Melanoma with Secondary Adrenal Insufficiency: A Case Series
- (2011) Le Min et al. Endocrine Practice
- Clinical Applications of Diabetes Antibody Testing
- (2009) Polly J. Bingley JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started